Last10K.com

Contineum Therapeutics, Inc. (1855175) SEC Filing 8-K Material Event for the period ending Tuesday, April 9, 2024

SEC Filings

1855175 Corporate News

  • Bylaw Change
    Financial Exhibit

    April 2024

1855175 Registration of Securities

Contineum Therapeutics, Inc.

HISTORY TOOLS
CIK: 1855175

View differences made from one to another to evaluate Contineum Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Contineum Therapeutics, Inc..

Continue

Assess how Contineum Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Contineum Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Contineum Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 3.1: Articles Of Incorporation
Exhibit 3.2: Articles Of Incorporation
CIK: 1855175
Form Type: 8-K Corporate News
Accession Number: 0001193125-24-090917
Submitted to the SEC: Tue Apr 09 2024 4:49:49 PM EST
Accepted by the SEC: Tue Apr 09 2024
Period: Tuesday, April 9, 2024
Industry: Pharmaceutical Preparations
Events:
  1. Bylaw Change
  2. Financial Exhibit

External Resources:
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/1855175/0001193125-24-090917.htm